Vistagen Therapeutics (VTGN) Current Assets (2017 - 2025)
Historic Current Assets for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $63.2 million.
- Vistagen Therapeutics' Current Assets fell 2968.17% to $63.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $63.2 million, marking a year-over-year decrease of 2968.17%. This contributed to the annual value of $82.1 million for FY2025, which is 3198.42% down from last year.
- According to the latest figures from Q4 2025, Vistagen Therapeutics' Current Assets is $63.2 million, which was down 2968.17% from $78.9 million recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Current Assets peaked at $128.1 million during Q4 2023, and registered a low of $11.6 million during Q2 2023.
- For the 5-year period, Vistagen Therapeutics' Current Assets averaged around $74.2 million, with its median value being $80.5 million (2025).
- Its Current Assets has fluctuated over the past 5 years, first soared by 648888.12% in 2021, then tumbled by 7894.52% in 2023.
- Vistagen Therapeutics' Current Assets (Quarter) stood at $86.8 million in 2021, then crashed by 69.97% to $26.1 million in 2022, then skyrocketed by 391.66% to $128.1 million in 2023, then dropped by 29.8% to $89.9 million in 2024, then fell by 29.68% to $63.2 million in 2025.
- Its Current Assets stands at $63.2 million for Q4 2025, versus $78.9 million for Q3 2025 and $66.7 million for Q2 2025.